Denali Therapeutics Inc.
NASDAQ:DNLI
15.15 (USD) • At close March 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 330.531 | 108.463 | 48.661 | 335.659 | 26.678 | 129.16 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 16.726 | 7.032 | 5.609 | 212.615 | 193.382 | 7.415 | 3.082 | 1.469 | 0.121 |
| Gross Profit
| 0 | 313.805 | 101.431 | 43.052 | 123.044 | -166.704 | 121.745 | -3.082 | -1.469 | -0.121 |
| Gross Profit Ratio
| 0 | 0.949 | 0.935 | 0.885 | 0.367 | -6.249 | 0.943 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 396.44 | 423.876 | 358.732 | 265.353 | 212.615 | 193.382 | 143.183 | 74.46 | 75.702 | 11.571 |
| General & Administrative Expenses
| 105.438 | 103.354 | 90.475 | 79.059 | 60.326 | 46.48 | 32.349 | 15.68 | 11.731 | 5.108 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 105.438 | 103.354 | 90.475 | 79.059 | 60.326 | 46.48 | 32.349 | 15.68 | 11.731 | 5.108 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 501.878 | 527.23 | 449.207 | 344.412 | 272.941 | 239.862 | 175.532 | 90.14 | 87.433 | 16.679 |
| Operating Income
| -487.341 | -196.699 | -340.744 | -295.751 | 62.718 | -213.184 | -46.372 | -90.14 | -87.433 | -16.679 |
| Operating Income Ratio
| 0 | -0.595 | -3.142 | -6.078 | 0.187 | -7.991 | -0.359 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 64.636 | 51.505 | 14.774 | 4.595 | 9.241 | 15.219 | 10.132 | 1.955 | 0.781 | -0.109 |
| Income Before Tax
| -422.705 | -145.194 | -325.97 | -291.156 | 71.959 | -197.965 | -36.24 | -88.185 | -86.652 | -16.788 |
| Income Before Tax Ratio
| 0 | -0.439 | -3.005 | -5.983 | 0.214 | -7.421 | -0.281 | 0 | 0 | 0 |
| Income Tax Expense
| -0.068 | 0.03 | 0.021 | -0.575 | 0.823 | -0.351 | 10.132 | -3.082 | 0 | 0 |
| Net Income
| -422.773 | -145.224 | -325.991 | -290.581 | 71.136 | -197.614 | -36.24 | -88.185 | -86.652 | -16.788 |
| Net Income Ratio
| 0 | -0.439 | -3.006 | -5.972 | 0.212 | -7.407 | -0.281 | 0 | 0 | 0 |
| EPS
| -2.57 | -1.06 | -2.6 | -2.39 | 0.65 | -2.07 | -0.39 | -5.89 | -13.49 | -5.58 |
| EPS Diluted
| -2.57 | -1.06 | -2.6 | -2.39 | 0.63 | -2.07 | -0.39 | -5.89 | -13.49 | -5.58 |
| EBITDA
| -487.341 | -179.973 | -330.361 | -287.158 | 62.718 | -205.193 | -38.957 | -87.058 | -85.964 | -15.058 |
| EBITDA Ratio
| 0 | -0.544 | -3.046 | -6.078 | 0.187 | -7.991 | -0.359 | 0 | 0 | 0 |